|
Treatment Modality
|
Agreement between the expertise
|
|---|
|
Strategy
|
MDT versus ESMO
|
MDT versus NCCN
|
ESMO versus NCCN
|
|---|
| |
N
|
(%)
|
N
|
(%)
|
N
|
(%)
|
|---|
|
Chemotherapy
|
|
Overalla
|
551/975
|
(57)
|
462/975
|
(47)
|
320/1065
|
(30)
|
|
Aggressive
|
628/975
|
(64)
|
616/975
|
(63)
|
416/1065
|
(39)
|
|
Conservative
|
729/975
|
(75)
|
731/975
|
(75)
|
721/1065
|
(68)
|
|
Endocrine therapy
|
|
Overalla
|
853/1002
|
(85)
|
840/1002
|
(84)
|
976/1065
|
(92)
|
|
Aggressive
|
970/1002
|
(97)
|
953/1002
|
(95)
|
1024/1065
|
(96)
|
|
Conservative
|
858/1002
|
(86)
|
861/1002
|
(86)
|
976/1065
|
(92)
|
|
Trastuzumab
|
|
Overalla
|
437/456
|
(96)
|
437/456
|
(96)
|
1047/1065
|
(98)
|
|
Aggressive
|
444/456
|
(97)
|
446/456
|
(98)
|
1058/1065
|
(99)
|
|
Conservative
|
437/456
|
(98)
|
440/456
|
(97)
|
1047/1065
|
(98)
|
- Abbreviations: MDT multidisciplinary team meeting, ESMO European Society for Medical Oncology guideline, NCCN National Comprehensive Cancer Network guideline
- aOverall – three-way grouping of “Recommended”, “For discussion”, “Not recommended”
